Literature DB >> 17374731

BRCA1 regulates IFN-gamma signaling through a mechanism involving the type I IFNs.

Niamh E Buckley1, Alison M Hosey, Julia J Gorski, James W Purcell, Jude M Mulligan, D Paul Harkin, Paul B Mullan.   

Abstract

BRCA1 encodes a tumor suppressor gene that is mutated in the germ line of women with a genetic predisposition to breast and ovarian cancer. BRCA1 has been implicated in a number of important cellular functions including DNA damage repair, transcriptional regulation, cell cycle control, and ubiquitination. Using an Affymetrix U95A microarray, IRF-7 was identified as a BRCA1 transcriptional target and was also shown to be synergistically up-regulated by BRCA1 specifically in the presence of IFN-gamma, coincident with the synergistic induction of apoptosis. We show that BRCA1, signal transducer and activator of transcription (STAT)-1, and STAT2 are all required for the induction of IRF-7 following stimulation with IFN-gamma. We also show that the induction of IRF-7 by BRCA1 and IFN-gamma is dependent on the type I IFNs, IFN-alpha and IFN-beta. We show that BRCA1 is required for the up-regulation of STAT1, STAT2, and the type I IFNs in response to IFN-gamma. We show that BRCA1 is localized at the promoters of the molecules involved in type I IFN signaling leading to their up-regulation. Blocking this intermediary type I IFN step using specific antisera shows the requirement for IFN-alpha and IFN-beta in the induction of IRF-7 and apoptosis. Finally, we outline a mechanism for the BRCA1/IFN-gamma regulation of target genes involved in the innate immune response, which is dependent on type I IFN signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17374731     DOI: 10.1158/1541-7786.MCR-06-0250

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  19 in total

Review 1.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

2.  Derepression of HMGA2 via removal of ZBRK1/BRCA1/CtIP complex enhances mammary tumorigenesis.

Authors:  Kazi Mokim Ahmed; Connie Y Tsai; Wen-Hwa Lee
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

3.  Decreased 7,12-dimethylbenz[a]anthracene-induced carcinogenesis coincides with the induction of antitumor immunities in adult female B6C3F1 mice pretreated with genistein.

Authors:  Tai L Guo; Rui P Chi; Denise M Hernandez; Wimolnut Auttachoat; Jian F Zheng
Journal:  Carcinogenesis       Date:  2007-10-04       Impact factor: 4.944

4.  Comparison of transcriptional profiles between CD4+ and CD8+ T cells in HIV type 1-infected patients.

Authors:  Chaoyu Xu; Baochun Ye; Zongping Han; Mingxing Huang; Yujia Zhu
Journal:  AIDS Res Hum Retroviruses       Date:  2013-09-17       Impact factor: 2.205

5.  Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.

Authors:  Robert M Samstein; Chirag Krishna; Xiaoxiao Ma; Xin Pei; Ken-Wing Lee; Vladimir Makarov; Fengshen Kuo; Jonathan Chung; Raghvendra M Srivastava; Tanaya A Purohit; Douglas R Hoen; Rajarsi Mandal; Jeremy Setton; Wei Wu; Rachna Shah; Besnik Qeriqi; Qing Chang; Sviatoslav Kendall; Lior Braunstein; Britta Weigelt; Pedro Blecua Carrillo Albornoz; Luc G T Morris; Diana L Mandelker; Jorge S Reis-Filho; Elisa de Stanchina; Simon N Powell; Timothy A Chan; Nadeem Riaz
Journal:  Nat Cancer       Date:  2020-11-16

6.  Up-regulation of the interferon-related genes in BRCA2 knockout epithelial cells.

Authors:  Hong Xu; Jian Xian; Emmanuelle Vire; Steven McKinney; Vivien Wei; Jason Wong; Rebecca Tong; Tony Kouzarides; Carlos Caldas; Samuel Aparicio
Journal:  J Pathol       Date:  2014-08-28       Impact factor: 7.996

7.  Network Analysis of the Systemic Response to Fasciola hepatica Infection in Sheep Reveals Changes in Fibrosis, Apoptosis, Toll-Like Receptors 3/4, and B Cell Function.

Authors:  Yan Fu; John A Browne; Kate Killick; Grace Mulcahy
Journal:  Front Immunol       Date:  2017-04-25       Impact factor: 7.561

8.  An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.

Authors:  Andrew E Teschendorff; Ahmad Miremadi; Sarah E Pinder; Ian O Ellis; Carlos Caldas
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

9.  BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers.

Authors:  Niamh E Buckley; Caoimhe B Nic An tSaoir; Jaine K Blayney; Lisa C Oram; Nyree T Crawford; Zenobia C D'Costa; Jennifer E Quinn; Richard D Kennedy; D Paul Harkin; Paul B Mullan
Journal:  Nucleic Acids Res       Date:  2013-07-17       Impact factor: 16.971

10.  TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.

Authors:  Zenobia C D'Costa; Catherine Higgins; Chee Wee Ong; Gareth W Irwin; David Boyle; Darragh G McArt; Karen McCloskey; Niamh E Buckley; Nyree T Crawford; Lalitha Thiagarajan; James T Murray; Richard D Kennedy; Karl A Mulligan; D Paul Harkin; David J J Waugh; Chris J Scott; Manuel Salto-Tellez; Richard Williams; Paul B Mullan
Journal:  Oncotarget       Date:  2014-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.